SAN DIEGO --(BUSINESS WIRE)--May 10, 2022-- DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain , Executive Vice President and Chief Financial Officer, will present an update on the company at the following upcoming investor conferences: BofA Securities 2022 Healthcare Conference on

SAN DIEGO --(BUSINESS WIRE)--Apr. 28, 2022-- DexCom, Inc. has updated its first quarter 2022 earnings call due to technical difficulties with the conference call provider. The conference call will now start at 5:30 p.m. (Eastern Time) . The link to the webcast will be available on the DexCom, Inc.

SAN DIEGO --(BUSINESS WIRE)--Apr. 28, 2022-- DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2022 . First Quarter 2022 Financial Highlights: Revenue grew 25% versus the same quarter of the prior year to $628.8 million on a reported basis

New portfolio of continuous glucose monitoring systems includes Dexcom ONE, Dexcom G6 and the upcoming Dexcom G7, which recently received CE Mark and is currently under FDA review 1 The expanded range of products offers the most innovative, connected and accessible CGM options available for people

Beginning mid-April, TRICARE® members will have faster and more convenient access to the Dexcom G6 Continuous Glucose Monitoring (CGM) System Dexcom G6 will be available as a brand-name formulary pharmacy benefit to military members, retirees and their families SAN DIEGO – April XX, 2022 – DexCom,

Report advances Dexcom’s environmental, social, and governance (ESG) transparency by providing new disclosures including company’s first Sustainability Accounting Standards Board (SASB) index SAN DIEGO --(BUSINESS WIRE)--Apr. 7, 2022-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time

On the heels of the latest NICE guidelines, Dexcom ONE is in review by NHS England for addition to the Drug Tariff LONDON --(BUSINESS WIRE)--Apr. 1, 2022-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the new

SAN DIEGO --(BUSINESS WIRE)--Mar. 31, 2022-- DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2022 financial results after market close on Thursday, April 28, 2022 . Management will hold a conference call to review the company's first quarter 2022 performance

SAN DIEGO --(BUSINESS WIRE)--Mar. 25, 2022-- DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today that its Board of Directors has approved a four-for-one forward split (the “Stock Split”) of Dexcom’s common stock.

The best-selling real-time CGM in the world 1 is now more powerful and easier to use with a small, all-in-one wearable and completely redesigned mobile app New system has the fastest sensor warmup on the market,* with no fingersticks † or scanning required Dexcom G7 builds on the trusted